UFP Technologies, Inc. to Present and Host 1x1 Investor Meetings at the Goldman Sachs 46th Annual Global Healthcare Conference
NEWBURYPORT, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), today announced that Jeffrey Bailly, Chairman and CEO, and Ron Lataille, Sr. Vice President & CFO, will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025. UFP's fireside chat is scheduled to begin at 11:20 AM ET.
About UFP Technologies, Inc.
UFP Technologies is a designer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging, and other highly engineered custom products. UFP is an important link in the medical device supply chain and a valued outsourcing partner to many of the top medical device manufacturers in the world. The Company's single-use and single-patient devices and components are used in a wide range of medical devices and packaging for minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants.
Contact:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
40 minutes ago
- Globe and Mail
Prediction: 2 Artificial Intelligence (AI) Stocks That Will Be Worth More Than Palantir Within 1 Year
Artificial intelligence (AI) has been the driving force behind the stock market's gains since the release of ChatGPT in November 2022. Few companies have benefited more from the advancements and excitement around generative AI than Palantir Technologies (NASDAQ: PLTR). Palantir's financial results have been fantastic as it expands its customer base and use cases within enterprises. Those results were boosted by Palantir's Artificial Intelligence Platform (AIP), which makes it easy to glean new insights from big data sets. As a result, the company's stock has climbed 1,630% since December 2022 and sports a market cap of over $300 billion, as of this writing. Palantir is now one of the most valuable companies in the world. But a couple of other AI innovators could overtake it within the next year. Here are two AI stocks I think will be worth more than Palantir in the near future. The biggest challenge for Palantir stock As mentioned, Palantir has produced excellent financial results. Its AIP makes it easier for nontechnical users to take advantage of its core software, which helps businesses and governments make decisions and gain insights based on large, often disparate datasets. As a result, more businesses can use Palantir, and more people and departments within each business can use it. That's led to strong revenue growth over the last few years. Revenue grew 39% year over year in the first quarter. Moreover, as a software company, Palantir's able to produce tremendous operating leverage, since the marginal cost of taking on another customer is minimal. As a result, operating margin expanded to 44% last quarter. Management expects to produce that level of profitability for the full year as well. There's no doubt Palantir's producing excellent operating results. The challenge for the stock is its valuation. Shares currently trade for more than 75 times management's outlook for 2025 revenue. Its enterprise value is 175 times analyst expectations for earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months. Analysts put a median price target of $100 per share on Palantir, a 24% drop from its current price. Only a handful rate the stock "overweight" or "buy." To say that it's expensive may be an understatement. Meanwhile, these two stocks look undervalued despite the potential for AI to help grow their businesses substantially over the next few years. 1. Salesforce Salesforce (NYSE: CRM) is looking to take its dominant position in enterprise software solutions for sales and marketing, customer service, and data management, and help businesses harness the power of AI within those systems. Its solution is called Agentforce, which rolled out late last year. Agentforce allows businesses to use their data and systems to create AI agents that can make decisions and take actions without human intervention. The company has signed around 8,000 Agentforce contracts as of the end of May. It's producing annual recurring revenue of around $100 million. When combined with its data management solutions, it's a $1 billion business just a few months after launching. That said, it's still just a small part of Salesforce's overall business. Management expects sales to top $41 billion this year, with an operating margin of 34%. That's supported by stable subscription revenue from its core enterprise software offerings. Despite strong earnings results and raising its full-year outlook last month, investors sent the stock price lower following its most recent earnings report. There could be a couple of reasons. Management announced the acquisition of Informatica for $8 billion, increasing execution risk for the business. If the acquisition doesn't meaningfully accelerate its data management business, investors could see it as a waste of money. The other detail that came in below expectations was its remaining performance obligations. But strong uptake in Agentforce and management increasing its full-year guidance should offset the weakness there. Salesforce stock currently trades for just 6 times management's revenue guidance. Its forward P/E ratio of just 23 looks very attractive. Analysts seem to agree, putting a median price target of $355 on the stock, a 35% upside from its price as of this writing. That could put the company's value well over $300 billion within a year. 2. Adobe Adobe (NASDAQ: ADBE) has taken innovations in AI over the last few years and applied them to its own products across both its creative suite of software (Photoshop, Lightroom, Premiere Pro, etc.) and its marketing, analytics, and productivity software (Acrobat, e-signing, etc.). It touts its FireFly model as "commercial safe," meaning it was trained on stock images and data that users can freely publish to their own websites and other online accounts. Adobe's AI integrations have helped it increase pricing for its software, but they also provide new opportunities to bring in customers. It integrated AI with Adobe Express, its online creative service, and it's seen an uptick in new customer accounts and conversion from free accounts to paid accounts. It also introduced GenStudio, which combines its creative and marketing software and allows users to create new ad campaigns and managing existing ones using natural language prompts. Management says it ended the first quarter with $125 million in annual recurring revenue, directly attributable to AI services. It expects that number to double by year-end. But more impressive is the $3.5 billion in AI-influenced annual recurring revenue across its existing portfolio. That stems from increased retention rates and higher revenue per user. That's already a significant chunk of the businesses' $23 billion annual revenue, and it's growing quickly. Many investors see generative AI as a significant threat to Adobe's creative software. But Adobe is fully entrenched in the creative business, and there's a strong network effect and high switching costs involved with leaving the ecosystem. Understanding how to use Adobe's creative software is practically a requirement for any designer, photographer, or film editor. As Adobe continues to advance its own AI capabilities, it stands to strengthen its competitive moat. Adobe stock trades for about 7 times management's estimate for 2025 revenue. Its forward P/E sits below 20. Meanwhile, management's outlook for the next three years suggests double-digit revenue growth while exhibiting operating leverage. At its current price, the stock looks like a bargain. The median price target on Wall Street is $477.50, implying 19% upside from the stock price, as of this writing. I believe the upside could be even greater, based on strong earnings growth and multiple expansion, and the company could be worth closer to $250 billion within a year. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor 's total average return is994% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025
Globe and Mail
an hour ago
- Globe and Mail
Trump doubles down on steel, aluminum tariffs
On Tuesday, U.S. President Donald Trump signed a new executive order that raised tariffs on steel and aluminum from 25 per cent to 50 per cent. One Canadian steel producer said this means that their American business is now 'unviable'. Jason Kirby is a staff reporter for The Globe's Report on Business section. He explains why these higher steel and aluminum tariffs could mean higher prices on nearly everything, and what may have contributed to Trump's escalation. Questions? Comments? Ideas? Email us at thedecibel@
CBC
an hour ago
- CBC
England is launching a gonorrhea vaccine. Is Canada next?
Social Sharing England will soon begin administering a vaccine to high-risk individuals that may reduce their chances of contracting gonorrhea, but a similar program is not yet in the cards for Canada. According to studies cited by England's National Health Service, the 4CMenB vaccine, which is presently used in Canada for immunization against meningitis B, has an effectiveness of 32.7 to 42 per cent against gonorrhea. To combat rising infection rates, the health service said last month it will begin administering the vaccine free of charge in August for those deemed to be at high risk of contracting gonorrhea, including gay and bisexual men who have a history of sexually transmitted infection or multiple sex partners. But the vaccine has not been authorized for this use in Canada, even as cases of gonorrhea continue to rise across the country. According to the most recent national statistics, rates of the sexually transmitted infection more than tripled in Canada from 2010 to 2022, going from 11,381 in 2010 to 35,956 in 2022. Gonorrhea, often referred to as "the clap," is passed on through oral, anal or genital sex. People who've been infected, especially women, often show no symptoms at all. If left untreated, it can have serious health risks. In an interview with CBC News on Monday, Calgary physician Caley Shukalek, the chief medical officer for Freddie, an online service that focuses on 2SLGBTQ+ health care, said it's still too soon to know how effective the 4CMenB vaccine will be at preventing new gonorrhea infections. Early research hasn't been conclusive either, Shukalek said, citing another study conducted by researchers in France that suggested the vaccine may not have any statistical effect on gonorrhea rates. "I think in the medical community, there's still a bit of skepticism," he said, noting that more research needs to be done before the true impact is known. The potential upside is promising enough, however, that Shukalek said he has begun prescribing the vaccine to some people who are willing to pay for it out of pocket or through private health insurance. "Its safety is very well established, so for those at high risk of STIs, I think this is a very worthwhile thing and something that could be considered," he said. "But because it's kind of what we call off-label, it absolutely is something that needs to be a discussion between a prescriber and a patient to make sure that it's the right decision based on their individual risk." The vaccine is typically administered in two phases, he said, with the second dose coming at least four weeks after the first. Regular testing key for preventing spread Chris Aucoin is the executive director of the Health Equity Alliance of Nova Scotia, a group that advocates for those living with HIV and members of the 2SLGBTQ+ community. He's aware of the latest research on the use of the 4CMenB vaccine to help prevent the spread of gonorrhea, but notes that even if it's approved, it would only be one part of a potential prevention strategy. Aucoin said the best thing people can do now and in the future to prevent the spread of gonorrhea is to get tested regularly. "If people are concerned about gonorrhea rates, which are too high … the biggest factor in that for me is the fact that people don't test regularly enough." He said the recent launch of Nova Scotia's STI Care Now program, which mails out free at-home testing kits for chlamydia, gonorrhea and HIV to anyone interested across the province, is a positive step toward making this easier. "We now have a tool that's accessible to them in a way that's never been the case in Nova Scotia," he said. In a statement, the Public Health Agency of Canada said the National Advisory Committee on Immunization is monitoring the latest research on the 4CMenB vaccine. In a 2023 report, the advisory committee noted that although the vaccine is not currently authorized for this purpose, it may "offer some level of cross-protection against gonococcal infection." The agency said it expects the committee to further assess this possibility as more evidence becomes available. Nova Scotia Health echoed this statement, noting that it takes its cues on immunization from the committee. Those looking to pay out of pocket for the vaccine in the private market would be looking at around $200 per dose, the department said. In 2024, there were 368 new cases of gonorrhea reported in Nova Scotia.
